Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Venous Thrombosis IV: Nursing Management

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Sudden Cardiac Arrest in Athletes.

The New England journal of medicine·2026

Same author

Livedoid vasculopathy in hemoglobinopathy-associated chronic leg ulcers.

Annals of hematology·2024

Same author

Antibody Fingerprints Linking Adenoviral Anti-PF4 Disorders.

The New England journal of medicine·2024

Same author

How I treat the co-occurrence of venous and arterial thromboembolism: anticoagulation, antiplatelet therapy, or both?

Blood·2024

Same author

More on Adenovirus-Associated Thrombocytopenia, Thrombosis, and VITT-like Antibodies. Reply.

The New England journal of medicine·2023

Same author

Evaluating complement dysregulation in livedoid vasculopathy using a functional assay.

Blood advances·2023

Same journal

An Update on the Role of Renal Artery Denervation in the Treatment of Hypertension.

Current treatment options in cardiovascular medicine·2026

Same journal

Advancements and Challenges in Contemporizing Care for Adult Patients with Congenital Heart Disease and Advanced Heart Failure: An Update on Application of Modern Heart Failure Technologies.

Current treatment options in cardiovascular medicine·2026

Same journal

Evolving Decongestion Strategies in the Management of Acute Heart Failure.

Current treatment options in cardiovascular medicine·2025

Same journal

Advanced Electroanatomic Mapping: Current and Emerging Approaches.

Current treatment options in cardiovascular medicine·2025

Same journal

Metabolic Reprogramming in Heart Failure: From Energy Starvation to Therapeutic Targets.

Current treatment options in cardiovascular medicine·2025

Same journal

Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.

Current treatment options in cardiovascular medicine·2025

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 24, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

Thrombophilia: 2009 update.

Pat Foy¹, Stephan Moll

¹Department of Medicine, Division of Hematology-Oncology, University of North Carolina School of Medicine, CB7035, Chapel Hill, NC 27599, USA.

Current Treatment Options in Cardiovascular Medicine

|March 18, 2009

Summary

This summary is machine-generated.

Thrombophilia testing is mainly for strong inherited clotting disorders, not routine screening for provoked venous or arterial thrombosis. Identifying strong thrombophilias guides long-term anticoagulation and family screening decisions.

More Related Videos

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Related Experiment Videos

Last Updated: Jun 24, 2026

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time

Published on: May 24, 2020

Area of Science:

Hematology
Vascular Medicine
Clinical Genetics

Background:

Venous thromboembolism (VTE) is linked to coagulation system disturbances.
Thrombophilias predisposing to arterial thromboembolism are less understood.
Fibrinolytic pathway abnormalities show weak, inconsistent links to arterial thrombosis.

Purpose of the Study:

To clarify the role of thrombophilia testing in clinical practice.
To differentiate between strong and weak thrombophilias.
To guide testing decisions for patients and family members.

Main Methods:

Review of current literature and testing guidelines.
Analysis of risk factors for venous and arterial thrombosis.
Evaluation of clinical consequences of identifying specific thrombophilias.

Main Results:

Routine thrombophilia screening is not indicated for provoked VTE or arterial thrombosis with risk factors.
Heterozygous Factor V Leiden (FVL) and prothrombin 20210 mutations have minimal impact on recurrent VTE risk after anticoagulation cessation.
Strong thrombophilias include antithrombin deficiency, antiphospholipid antibody syndrome, homozygous FVL, double heterozygosity, protein C deficiency, and possibly protein S deficiency.

Conclusions:

Thrombophilia testing is primarily indicated for strong inherited thrombophilias.
Identifying strong thrombophilias influences decisions on long-term anticoagulation for unprovoked VTE.
Testing can guide treatment choices for unexplained arterial events and inform family screening and counseling.